Trending...
- Colorfront Launches New Mac App For Creating Apple Immersive Video
- Michele Mundy's "Divinely Tailored" Gains Momentum
- Legacy of Learning Benefit to Support Scholarships at Grace Montessori School
AVENTURA, Fla. - PennZone -- Dr. Jeff Gelblum, Neurologist at First Choice Neurology, has brought together clinical, imaging, and laboratory capabilities to provide rapid diagnosis and treatment to individuals suffering from Alzheimer's disease.
The patient journey of Alzheimer's evaluation and management involves a clinical assessment to determine the level of cognitive impairment, and imaging studies of the brain, MRI, and PET scans to identify the presence of brain amyloid plaques. Also included are laboratory capabilities to inform the tolerability of the new anti-Alzheimer medication, and an experienced infusion team capable of providing the new class of FDA-approved medication in a comfortable setting.
Dr. Gelblum's highly integrated program will eliminate the long delays and fragmented care that typically plague patients seeking Alzheimer's treatment.
He observes, "that the new class of disease-modifying treatments are only approved in mild Alzheimer's which offers only a short window of opportunity to treat. In the US and abroad, it can often take up to a year to get a neurology appointment, and by that point, the patient may have progressed to a point where they might no longer respond to treatment."
More on The PennZone
Dr. Gelblum's program eliminates the delay and provides a quick and comprehensive work-up in the Aventura medical district, just north of Miami, Florida.
Dr. Gelblum boasts that "within 48 hours we can diagnose and begin infusion therapy. This means that the patient can check in to our on-campus hotel on a Tuesday evening, undergo evaluation in our clinic Wednesday morning, receive diagnostic testing Wednesday and Thursday, and then obtain their infusion treatment on Friday."
For those patients who reside out of town, his infusion center can dispense medication to-go for follow-up infusion treatments in their hometown medical facility. This is ideal for out-of-town patients who may not have easy access to a neurologist. He can then follow the patient remotely via telehealth.
His Aventura clinic is easily accessible via Miami or Fort Lauderdale international airports.
Dr. Gelblum has a global patient population who has discovered the ease of access and convenience of care provided by this program. He has patients from the UK, Spain, France, Israel, Russia, South Korea, Central and South America, and the Caribbean. They are diagnosed in his Aventura clinic and then followed up remotely via Skype, WhatsApp, FaceTime, or any manner of live audiovisual interface.
More on The PennZone
Dr. Gelblum observes, "that in this day and age of disease-modifying therapy and instantaneous telecommunications, it is unacceptable for medically necessary neurological care and treatment to be delayed."
He looks forward to welcoming Alzheimer patients from all over to his Aventura, Florida clinic.
About Jeffrey Gelblum, MD, FAAN
Dr. Jeff Gelblum is a neurologist with First Choice Neurology located in Aventura, Florida. He is considered a global thought leader in the neurologic treatment of Alzheimer's, dementia, seizure disorders, Parkinson's, diabetic and peripheral nerve disorder, Familial Amyloid Polyneuropathy, Covid Long-Hauler, trauma, and chronic pain, and has hosted educational symposia in the U.S. and overseas. To learn more about Dr. Gelblum, visit https://www.fcneurology.net/business-directory/788/jeffrey-gelblum-md/
The patient journey of Alzheimer's evaluation and management involves a clinical assessment to determine the level of cognitive impairment, and imaging studies of the brain, MRI, and PET scans to identify the presence of brain amyloid plaques. Also included are laboratory capabilities to inform the tolerability of the new anti-Alzheimer medication, and an experienced infusion team capable of providing the new class of FDA-approved medication in a comfortable setting.
Dr. Gelblum's highly integrated program will eliminate the long delays and fragmented care that typically plague patients seeking Alzheimer's treatment.
He observes, "that the new class of disease-modifying treatments are only approved in mild Alzheimer's which offers only a short window of opportunity to treat. In the US and abroad, it can often take up to a year to get a neurology appointment, and by that point, the patient may have progressed to a point where they might no longer respond to treatment."
More on The PennZone
- Philadelphia Community Unites for Awareness 2 Wellness Annual Wellness Fair Focused on Healing, Hope
- West Park Arts Fest 2026 Returns to Philadelphia for a Day of Music, Art, and Cultural Celebration
- Project Pretzel Introduces a New System for Running Renovation Projects with Built In Contracts and Real Time Execution
- Freedomtech Solutions creates 'Global Data Centre Network (IDCN)'
- D&D Journey–Children with Disabilities Matter Names JBlair Brown as New PR & Marketing Director
Dr. Gelblum's program eliminates the delay and provides a quick and comprehensive work-up in the Aventura medical district, just north of Miami, Florida.
Dr. Gelblum boasts that "within 48 hours we can diagnose and begin infusion therapy. This means that the patient can check in to our on-campus hotel on a Tuesday evening, undergo evaluation in our clinic Wednesday morning, receive diagnostic testing Wednesday and Thursday, and then obtain their infusion treatment on Friday."
For those patients who reside out of town, his infusion center can dispense medication to-go for follow-up infusion treatments in their hometown medical facility. This is ideal for out-of-town patients who may not have easy access to a neurologist. He can then follow the patient remotely via telehealth.
His Aventura clinic is easily accessible via Miami or Fort Lauderdale international airports.
Dr. Gelblum has a global patient population who has discovered the ease of access and convenience of care provided by this program. He has patients from the UK, Spain, France, Israel, Russia, South Korea, Central and South America, and the Caribbean. They are diagnosed in his Aventura clinic and then followed up remotely via Skype, WhatsApp, FaceTime, or any manner of live audiovisual interface.
More on The PennZone
- Dual-Engine Growth Strategy Ignited: AI Infrastructure Breakout Meets Scalable Circular Economy Expansion: Marwynn Holdings, Inc. (N A S D A Q: MWYN)
- Super Bowl Champion Marvel Smith Inspires Launch of MVP-IQ Platform to Help Football Players Develop and Get Recruited Like the Pros
- The Future of Classic Cars in a World Moving Beyond Gasoline: How Electric Conversion Is Saving America's Automotive Heritage
- Xtel Communications Appoints David Appleman as VP of Strategic Sales
- L2 Aviation Acquires Advance Aero
Dr. Gelblum observes, "that in this day and age of disease-modifying therapy and instantaneous telecommunications, it is unacceptable for medically necessary neurological care and treatment to be delayed."
He looks forward to welcoming Alzheimer patients from all over to his Aventura, Florida clinic.
About Jeffrey Gelblum, MD, FAAN
Dr. Jeff Gelblum is a neurologist with First Choice Neurology located in Aventura, Florida. He is considered a global thought leader in the neurologic treatment of Alzheimer's, dementia, seizure disorders, Parkinson's, diabetic and peripheral nerve disorder, Familial Amyloid Polyneuropathy, Covid Long-Hauler, trauma, and chronic pain, and has hosted educational symposia in the U.S. and overseas. To learn more about Dr. Gelblum, visit https://www.fcneurology.net/business-directory/788/jeffrey-gelblum-md/
Source: First Choice Neurology
0 Comments
Latest on The PennZone
- World Cup Buzz Fuels Nayarit's Rise as Mexico's Pacific Standout
- Nayarit strengthens its position in Mexico's Culinary Elite with 8 restaurants in the 2026 Mexico Gastronomic Guide
- Winter Garden Ski Lake Home Sells for $2.05M in Cash Transaction, Highlighting Demand for Strategically Positioned Luxury Properties
- Strobert Tree Services' "50 Shades of Green" Campaign Encourages Arbor Day Action Across Delaware and Pennsylvania
- As Fluoride Debate Grips the Nation, Americans Turn to Whole-House Fluoride Filters for Answers
- FOCUS Hires Carrier-Side Operations Leader to Build the Next Generation of Insurance Service Delivery
- Adams Security Group LLC Launches New Website to Expand Professional Security Services Across Florida
- Presidential Acceleration of Psychedelic Therapies Enters a Defining Moment as Federal Policy, FDA Alignment & Breakthrough Neurotechnology Converge
- Peernovation And Inception Stratos Launch Joint Venture To Build A Global Peer-powered Performance Platform
- GDE Tree Services Expands Operations Across Logan, Ipswich and the Gold Coast
- UK AltNet FullFibre Solves IPv4 Shortage With netElastic BNG And CGNAT Networking Software
- Best Companies Group Opens Registration for Best Places to Work in Manufacturing Program
- Studica Robotics Receives 2026 Partner Excellence Award from FIRST® Robotics Canada
- Seven Games That Make You Think (and Smile) Earn 2026 Mensa Select® Honors
- Mark Schork Honored by Legal Intelligencer as Lawyer on the Fast Track
- New Research Reveals Gen Z Trusts Independent Sources Over Influencers — Exposing What We are Talker Calls "The Independent Validation Gap"
- Morphy's April 28 Premier Coins auction is a numismatist's dream, with 368 lots of antique and vintage US gold and silver coins and more
- New research identifies The Discovery Gap: Seven in 10 Americans say travel is no longer just about getting away
- PropAccount.com Adds Equities to Its Multi-Asset Prop Firm Platform, Opening the Door to the World's Largest Trading Market
- Ailias Launches Global Partner Programme for AI-Powered Conversational Digital Humans in Events and Experiences
